March 15, 2022 7:41am

However, I’d be nibling on the fallen and oversold which doesn’t mean there isn’t risk involved

Earnings: Athersys (ATHX)

Pre-open indications: 2 SELLs and 7 BUYs indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could or might happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are UP +0.02% (+7 points), S&P futures are UP +0.12% (+5 points) and NASDAQ futures are UP +0.34% (+45 points)

 

U.S. stock futures leaned upward on Tuesday as investors view daily the Russia-Ukraine conflict and hear of Covid-19 spike in China,

European stocks fell in trading as UK workers suffer biggest pay squeeze since 2014,

Asia-Pacific markets were limping along, though some losses were pared following the release of Chinese economic data that was far above expectations.

 

Henry’omics:

Monday, the Nasdaq extended its slide into a third day to cap the earlier session

Tuesday, word was a lockdown in China could worsen supply chain issues, after a surge in coronavirus cases suspended production in cities such as Shenzhen, a key manufacturing city. The Russia-Ukraine conflict had already led to a spike in commodities prices. <CNBC>

 

RegMed Investors’ (RMi) closing bell: “just when I thought sentiment would rebound and lift the cell and gene therapy sector.” … https://www.regmedinvestors.com/articles/12340

Ebb and flow –

·         March – 7 negative and 3 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ...  25 total to date

 

Companies in my headlights – It’s your decision; I provide ideas and context:

Maintaining BUY:

Beam Therapeutics (BEAM) closed down -$7.18 to $53.73 after Friday’s -$4.81 to $60.91, Thursday’s +$0.61 Wednesday’s +$2.64 and last Tuesday’s -$0.34) with a flat pre-open indication

Caribou Therapeutics (CRBU) closed down -$0.77 to $8.42 after Friday’s -$0.33, Thursday’s-$0.24 with a flat with a pre-open indication.

Editas Medicine (EDIT) closed down -$0.98 to $14.08 after Friday’s -$1.17 to $15.06 and Thursday’s -$0.40) with a flat pre-open indication.

Intellia Therapeutics (NTLA) closed down again -$2.49 to $58.80 after Friday’s-$4.62 to $61.29 and Thursday’s -$0.08 with a positive +$1.09 or +1.85% pre-open indication.

 

BUY:

Fate Therapeutics (FATE) closed down -$3.88 to $29.67 after Friday’s -$1.93, Thursday’s +$0.07, Wednesday’s +$2.64 and last Tuesday’s +$0.91 with a positive +$0.90 or +3.03% pre-open indication.

Global Blood Therapeutics (GBT) closed up +$0.58 to $28.39 with a positive +$1.12 or +3.95% pre-open indication.

Precigen (PGEN) closed down -$0.15 to $1.91 with a positive +$0.20 or +10.47% pre-open indication.

 

SELL:

Sage Therapeutics (SAGE) closed down -$0.36 to $30.71 after Friday’s -$1.08 to $31.07, Thursday’s +$0.61 Wednesday’s +$2.64 and last Tuesday’s -$0.34) with a negative -$0.56 or -1.82% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$3.36 to $58.06 after Friday’s -$1.01, Thursday’s +$0.01 with a negative -$0.56 or -0.96% pre-open indication.

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed flat on Monday with 28 shares traded after Friday’s +$0.39 to $4.30 with 1,602 shares traded, Thursday’s -$0.63 with 488 shares traded, Wednesday’s -$0.26 with 1,225 shares traded and last Tuesday’s flat (having been up +$0.14) with 1,142 shares traded …

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering …
  • BSTG is NOT going ANYWHERE without a cash infusion.

 

The BOTTOM LINE: today is definitely a throw-of-the-dice game.

It all depends on the Nasdaq.

Could a new rally be attempted after recent lows? Or perhaps it's beginning a significant new leg down in the ongoing sector rectification.

Even if the cell and gene therapy sector does rebound from these down sloping days, which doesn't mean that hard hit gene editing (one example group) equities will lead an uptrend, especially having been hit so hard – they’re my bellwethers.

Reiterating, “The time to ramp-up a few select sector BUYS; it’s kind of there. But right now, the cell and gene therapy has felt in a depreciation outage.”

Negative news is the bane of these days of March with everything that has been written and shown on the TV.

Fed policymakers meet this week (3/15-16) on St. Patrick’s Day (to drive the snakes into not, out of interest rates) … the Fed will almost certainly raise rates by a quarter point on Wednesday afternoon, and signal several more Fed rate hikes.

I believe many of the oversold show buy signals but, have usually reverse lower. Thus, a shaky sector set-up within the market might beget a correction hopefully not like January and February’s movement.

There is no clear trend, and no reason to make any BUYS -however, the better way of saying but … short-term pops are (to me) clearly evident.

As I have stated yesterday, “bounce, baby, bounce”.

Earnings’ reporting on the horizon:

·         Athersys (ATHX), Today

·         Cellectis SA (CLLS) Thursday, 3/22

·         Brainstorm Cell Therapeutics (BCLI), Monday, 3/28

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication. 

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes purpose, courage, resolve and patience to stay the course of asking the questions without response!